Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

266
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
266
Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models00:57

Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models

394
Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...
394
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

347
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
347
Passive Diffusion: Overview and Kinetics01:17

Passive Diffusion: Overview and Kinetics

1.5K
Passive diffusion is a critical process that allows small lipophilic drugs to cross the cell membrane along a concentration gradient. This mechanism's efficiency depends on four primary factors: the membrane's surface area, the drug's lipid-water partition coefficient, the concentration gradient, and the membrane's thickness.
When administered orally, drugs establish a substantial concentration gradient between the gastrointestinal (GI) lumen and the bloodstream, expediting...
1.5K
Factors Influencing Drug Absorption: Drug Dissolution01:27

Factors Influencing Drug Absorption: Drug Dissolution

1.4K
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
1.4K
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

1.4K
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of suPAR and related proteins in kidney, heart diseases, and diabetes.

The Journal of clinical investigation·2026
Same author

Soluble urokinase receptor is a kidney-specific vasoconstrictor.

EBioMedicine·2025
Same author

Dysregulated Bone Marrow Contributes to Glomerular Injury through Soluble Factors.

Journal of the American Society of Nephrology : JASN·2025
Same author

Pathogenesis of Focal Segmental Glomerulosclerosis and Related Disorders.

Annual review of pathology·2025
Same author

Treatment of Podocytopathies: Risky Business and Our Personal Journey.

Journal of the American Society of Nephrology : JASN·2024
Same author

Circulating soluble urokinase plasminogen receptor is reduced by - and predicts early treatment response to therapeutic plasma exchange in septic shock.

Journal of critical care·2024

Related Experiment Video

Updated: Feb 26, 2026

Author Spotlight: Advancing the Use of Tissue Chip Technology for Studying Human Tissues
09:10

Author Spotlight: Advancing the Use of Tissue Chip Technology for Studying Human Tissues

Published on: January 12, 2024

3.8K

Circulating permeability factor suPAR: from concept to discovery to clinic.

Jochen Reiser1

  • 1Rush University Medical Center, Cohn Research Building, Suite 724, 1735 W. Harrison Street, Chicago, IL 60612, United States. jochen_reiser@rush.edu

Transactions of the American Clinical and Climatological Association
|July 23, 2013
PubMed
Summary

Focal segmental glomerulosclerosis (FSGS) involves podocyte injury, potentially caused by circulating factors like soluble urokinase plasminogen activator receptor (suPAR). Identifying suPAR offers new therapeutic avenues for FSGS patients.

More Related Videos

An In Vivo Blood-brain Barrier Permeability Assay in Mice Using Fluorescently Labeled Tracers
09:35

An In Vivo Blood-brain Barrier Permeability Assay in Mice Using Fluorescently Labeled Tracers

Published on: February 26, 2018

26.4K
In Vitro Permeation of FITC-loaded Ferritins Across a Rat Blood-brain Barrier: a Model to Study the Delivery of Nanoformulated Molecules
11:13

In Vitro Permeation of FITC-loaded Ferritins Across a Rat Blood-brain Barrier: a Model to Study the Delivery of Nanoformulated Molecules

Published on: August 22, 2016

8.4K

Related Experiment Videos

Last Updated: Feb 26, 2026

Author Spotlight: Advancing the Use of Tissue Chip Technology for Studying Human Tissues
09:10

Author Spotlight: Advancing the Use of Tissue Chip Technology for Studying Human Tissues

Published on: January 12, 2024

3.8K
An In Vivo Blood-brain Barrier Permeability Assay in Mice Using Fluorescently Labeled Tracers
09:35

An In Vivo Blood-brain Barrier Permeability Assay in Mice Using Fluorescently Labeled Tracers

Published on: February 26, 2018

26.4K
In Vitro Permeation of FITC-loaded Ferritins Across a Rat Blood-brain Barrier: a Model to Study the Delivery of Nanoformulated Molecules
11:13

In Vitro Permeation of FITC-loaded Ferritins Across a Rat Blood-brain Barrier: a Model to Study the Delivery of Nanoformulated Molecules

Published on: August 22, 2016

8.4K

Area of Science:

  • Nephrology
  • Molecular Biology
  • Pathology

Background:

  • Kidney filtration relies on podocytes, crucial for urine formation.
  • Disruption of podocytes leads to chronic kidney disease (CKD) and proteinuria.
  • Focal segmental glomerulosclerosis (FSGS) is a podocyte disease that can recur post-transplant.

Purpose of the Study:

  • To investigate the role of circulating factors in FSGS pathogenesis.
  • To identify potential blood-borne factors causing podocyte injury in FSGS.
  • To explore novel therapeutic targets for FSGS.

Main Methods:

  • Review of existing literature on podocyte biology and FSGS.
  • Analysis of patient data to identify circulating factors.
  • Biochemical assays to determine the mechanism of action of identified factors.

Main Results:

  • FSGS recurrence post-transplant suggests circulating causative factors.
  • Soluble urokinase plasminogen activator receptor (suPAR) identified in most FSGS patients.
  • suPAR binds to and activates podocyte beta 3 integrin, causing injury.

Conclusions:

  • suPAR is a promising circulating factor implicated in FSGS.
  • Targeting suPAR may offer a novel therapeutic strategy for FSGS.
  • Further research can lead to treatments for FSGS and related kidney diseases.